The industrial side of pharmaceutical outsourcing — capacity, chemistry, and the decisions behind them. Briefs from our analysis series, product updates, and featured CDMO partners.
Three questions about equipment, capacity and supply chains to help buyers assess an oral solid dose manufacturer, with UPM Pharmaceuticals as a company example.
22 signed deals in eight weeks, worth about US$24 billion in total potential value. Most of that depends on future milestones, and at least 8 of the 10 largest deals cover medicines not yet tested in patients.
Where its process development and specialist chemistry capabilities may fit a buyer's project.
Most sponsors choose a CRO on proposal price, brand recognition and a bid-defense meeting. Trials slip on what the proposal does not show: which sites activate, which team stays, how change orders are priced and who owns the data. A defensible shortlist is built on evidence a CRO can produce from its own records.
Peptide-based oncology programs use comparatively little API, but their manufacturing needs are exacting: small-scale GMP availability, specification control, analytical capability, inspection readiness, and a supply chain aligned to the patient.
How an independent US consultancy brings 30 years of industry experience to outsourced manufacturing, from vendor selection through commercial supply.
Most peptide CDMO selection frameworks were written when capacity was available. They ask reasonable questions at the wrong level of specificity — and where qualified commercial capacity is scarce, that imprecision costs a place in the queue. Six recurring failure modes, and the evidence that settles each one.
Solid-phase peptide synthesis consumes around 13,000 kg of material for every kg of API — forty to eighty times a small molecule. As GLP-1-class demand pushes volumes the industry has never operated at, solvent supply, recovery, and disposal are becoming the binding constraint.
New feature helps biotech and pharmaceutical companies discover qualified CDMOs by country through structured manufacturing intelligence and AI-powered supplier discovery.
We tracked more than twenty peptide facility announcements from 2024 to 2026. Only a handful add commercial-scale API capacity — and in 2026, consolidation quietly shrank the field rather than widening it.
A closer look at a US-based CDMO built for the late-stage journey — from formulation through commercial-scale oral solid and semi-solid manufacturing.
Two Phase 3 readouts have reset the ceiling for what peptide therapeutics can do. The more interesting story is everything the efficacy headline leaves out.